1. Link do strony z możliwością wsparcia forum:
https://pomagam.pl/forumdss_2020_22
2. Konta nowych użytkowników są aktywowane przez Administrację
(linki aktywacyjne nie działają) - zwykle w ciągu ok. 24 ÷ 48 h.
|
|
Autor |
Wiadomość |
Temat: Rak piersi - próby kliniczne firmy Roche w Polsce |
zosia bluszcz
Odpowiedzi: 0
Wyświetleń: 11263
|
Dział: Nowotwory piersi i ginekologiczne Wysłany: 2009-09-19, 08:14 Temat: Rak piersi - próby kliniczne firmy Roche w Polsce |
aktualnie rekrutujace pacjentki (Avastin, Herceptyna i Xeloda)
Zainspirowana watkiem na "Nowotwory damy rade" grzebnelam w necie i znalazlam ponizsze.
Poniewaz badania kliniczne prowadzone w PL sa na ogol chowane pod korcem maku wiec skopiowalam tutaj liste dot. polskich osrodkow.
Mozna ja odnalezc w tym linku
http://www.roche-trials.c.../catg10080.html
(panstwa sa wymienone w kolejnosci alfabetycznej).
Tamze klikniecie na tytul badania daje wglad w bardziej szczegolowe warunki rekrutacji.
Mam nadzieje, ze sie ta lista komus przyda.
Klucz do podstawowych warunkow:
*HER2-Positive Early Breast Cancer=dodatni HER2, wczesny rak piersi
*HER2 Positive Metastatic Breast Cancer=dodatni HER2, rak piersi z przerzutami
*HER2-Negative Metastatic Breast Cancer =ujemny HER2, rak piersi z przerzutami
*Maintenance Therapy in Patients With HER2-Negative Metastatic Breast Cancer =terapia podtrzymujaca, pacjentki z ujemnym HER2 i przerzutami
*Adjuvant Therapy in Triple Negative Breast Cancer= terapia adjuwantowa, rak potrojnie negatywny
*Metastatic Breast Cancer = rak piersi z przerzutami
Poland
Bialystok
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Recruiting
Bydgoszcz
A Study of Avastin (Bevacizumab) + Xeloda (Capecitabine)as Maintenance Therapy in Patients With HER2-Negative Metastatic Breast Cancer
Recruiting
Elblag
BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
Recruiting
Gdansk
A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
Recruiting
Gdansk
A Continuation Study of Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer
Recruiting
Gliwice
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Recruiting
Gliwice
A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
Recruiting
Krakow
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Recruiting
Krakow
A Study of Avastin (Bevacizumab) + Xeloda (Capecitabine)as Maintenance Therapy in Patients With HER2-Negative Metastatic Breast Cancer
Recruiting
Lodz
BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
Recruiting
Lodz
A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
Recruiting
Lublin
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Recruiting
Lublin
BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
Recruiting
Olsztyn
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Recruiting
Poznan
BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
Recruiting
Poznan
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Recruiting
Poznan
A Study of Avastin (Bevacizumab) + Xeloda (Capecitabine)as Maintenance Therapy in Patients With HER2-Negative Metastatic Breast Cancer
Recruiting
Rybnik
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Recruiting
Szczecin
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Recruiting
Ul. 28 Czerwca 1956 Nr 194
BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
Recruiting
Ul. 28 Czerwca 1956 Nr 194
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Recruiting
Warszawa
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Recruiting
Warszawa
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Recruiting
Warszawa
BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
Recruiting
Wroclaw
A Study of Avastin (Bevacizumab) + Xeloda (Capecitabine)as Maintenance Therapy in Patients With HER2-Negative Metastatic Breast Cancer
Recruiting
|
|
|